Several studies have indicated that osimertinib could be beneficial in patients with poor PS and EGFR T790M mutation-positive NSCLC following the progression of first- and second-generation EGFR-TKI treatments [16–19]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.